Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||Flotetuzumab||Phase I||Actionable||In a Phase I trial, Flotetuzumab (MGD006) demonstrated safety and preliminary efficacy in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, resulted in anti-leukemic activity in 57% (8/14) of patients and an overall response rate of 43% (6/14, 3 complete response, 1 CRi, 1 MLF, 1 partial response) (Blood 2017 130(Suppl 1):637).||detail...|
|PubMed Id||Reference Title||Details|
|Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome||Full reference...|